Delving into the Latest Updates on SENL101 with Synapse

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms

CD7-Specific CAR-T Cells(Hebei Senlangbio), KO7CAR, SENL101自体T细胞（河北森朗）

+ [4]

Target

CD7

Mechanism

CD7 inhibitors(T-cell antigen CD7 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

T-cell Acute Lymphoblastic Leukemia/LymphomaT-Cell LymphomaAdult Lymphoblastic Lymphoma

Inactive Indication

CD7 Positive T-Cell LeukemiaRefractory T Acute Lymphoblastic Leukemia

Originator Organization

Hebei Senlangbio Biotechnology Co., Ltd.

Active Organization

Hebei Senlangbio Biotechnology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

RegulationOrphan Drug (US)

Login to view timeline

主要研究目的：评价SENL101对于成人复发或难治性T淋巴母细胞淋巴瘤/白血病（T-LBL/ALL）患者的耐受性、安全性。次要研究目的：初步评价SENL101对于成人复发或难治性T淋巴母细胞淋巴瘤/白血病（T-LBL/ALL）患者治疗的有效性、药代动力学及药效动力学。

[Translation]

Primary study objective: To evaluate the tolerability and safety of SENL101 in adult patients with relapsed or refractory T-lymphoblastic lymphoma/leukemia (T-LBL/ALL). Secondary study objective: To preliminarily evaluate the efficacy, pharmacokinetics and pharmacodynamics of SENL101 in the treatment of adult patients with relapsed or refractory T-lymphoblastic lymphoma/leukemia (T-LBL/ALL).

Start Date04 Sep 2023

Sponsor / Collaborator

Hebei Senlangbio Biotechnology Co., Ltd.

NCT06136364 / RecruitingPhase 1

Open-label, Dose-escalation Phase 1 Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory T-LBL/ALL

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.

Start Date15 Aug 2023

Sponsor / Collaborator

Hebei Senlangbio Biotechnology Co., Ltd.

NCT05626400 / RecruitingNot Applicable

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T Lymphoblastic Leukemia and T Lymphoblastic Lymphoma

This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic leukemia or T lymphoblastic lymphoma.Meanwhile, PK/PD indexes of Senl-T7 were collected.

Start Date29 Aug 2022

Sponsor / Collaborator

Hebei Senlangbio Biotechnology Co., Ltd.

100 Clinical Results associated with SENL101

Login to view more data

100 Translational Medicine associated with SENL101

Login to view more data

100 Patents (Medical) associated with SENL101

Login to view more data

100 Deals associated with SENL101

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
T-cell Acute Lymphoblastic Leukemia/Lymphoma	Phase 1	CN	Hebei Senlangbio Biotechnology Co., Ltd.	04 Sep 2023
T-Cell Lymphoma	Phase 1	CN	Hebei Senlangbio Biotechnology Co., Ltd.	01 May 2022
Acute Lymphoblastic Leukemia	Phase 1	CN	Hebei Senlangbio Biotechnology Co., Ltd.	01 Oct 2020
CD7 Positive T-Cell Leukemia	Phase 1	CN	Hebei Senlangbio Biotechnology Co., Ltd.	01 Oct 2020
Refractory T Acute Lymphoblastic Leukemia	Phase 1	CN	Hebei Senlangbio Biotechnology Co., Ltd.	01 Oct 2020
Adult Lymphoblastic Lymphoma	Preclinical	US	Hebei Senlangbio Biotechnology Co., Ltd.	31 Aug 2023
Non-Hodgkin Lymphoma	Preclinical	CN	Hebei Senlangbio Biotechnology Co., Ltd.	12 Oct 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04938115 \| NCT04916860 (EHA2022) Manual	Phase 1	T-cell lymphoma recurrent \| Refractory Hematologic Malignancy	15	KO7CAR T-cells+Fludarabine Phosphate+Cyclophosphamide	rlyuwyqsfl(zogjjhhnxd) = ueiappyldc nvncxfcxsn (zxusbsakni ) View more	Positive	12 May 2022
NCT04938115 (ASH2021) Manual	Phase 1	Mixed phenotype acute leukemia CD7 Positive	5	Senl T7	zekisfrshn(hpuwncrmda) = ryoszcbcfg ppwtdndoqs (azltutsqub ) View more	Positive	05 Nov 2021